Conatus Is Gearing Up For A Compelling 2019 With Multiple Catalysts [Seeking Alpha]
CONATUS PHARMACEUTICALS INC (CNAT)
Last conatus pharmaceuticals inc earnings: 11/5 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.conatuspharma.com/investor-relations
Company Research
Source: Seeking Alpha
Conatus Is Gearing Up For A Compelling 2019 With Multiple Catalysts Summary Conatus Pharmaceuticals is expecting to release results from its phase 2b ENCORE-NF study using emricasan to treat patients with NASH fibrosis in the first half of 2019. Results from the phase 2b ENCORE-LF study using emricasan to treat patients with NASH cirrhosis are expected in mid-2019 and it entails a composite primary endpoint of event-free survival. The phase 2b ENCORE-PH study failed to meet the primary endpoint as it relates to HVPG, but an analysis of additional liver function and in clinical outcomes are expected mid-2019. The NASH market is expected to potentially be a $20 billion to $35 billion market opportunity in the coming years. New treatments are needed for patients with NASH cirrhosis because there is on average an estimated 17,000 people on a liver transplant waiting list at any given time. CNAT NASH Fibrosis The first study that is going to be read out is known as the phase 2b ENCORE-NF s
Show less
Read more
Impact Snapshot
Event Time:
CNAT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CNAT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CNAT alerts
High impacting CONATUS PHARMACEUTICALS INC news events
Weekly update
A roundup of the hottest topics